Yahoo Web Search

Search results

1. • 

     Sanofi's Dupixent gets U.S. approval to treat eczema in young children

     Reuters via Yahoo News· 2 years ago

     Dupixent is now the first approved treatment for moderate-to-severe eczema in young children, Sanofi...

2. • 

     Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids

     Zacks via Yahoo Finance· 1 year ago

     Sanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat...

3. • 

     The Next Humira? Insmed Catapults 119% On Its 'Very Attractive' Opportunity In Lung Disease.

     Investor's Business Daily· 1 hour ago

     Insmed stock catapulted Tuesday after the biotech company's experimental lung disease treatment...

4. • 

     Dupixent set for FDA review in adolescent chronic inflammatory sinus disease

     Pharmaceutical Technology via Yahoo Finance· 2 weeks ago

     Regeneron and Sanofi could soon be adding another indication to its blockbuster immunology drug...

5. • 

     Danielle Jonas says her eczema affected her self-esteem and deterred her from going on tour often...

     INSIDER via Yahoo News· 9 months ago

     Danielle Jonas opened up about her eczema journey in a recent interview with Insider.Courtesy of...

6. • 

     J&J gains another bispecific antibody with $1.25B skin drug buy

     BioPharma Dive via Yahoo Finance· 10 hours ago

     Dive Brief: Johnson & Johnson is adding to its portfolio of dual-targeting antibody drugs,...

7. • 

     Treatments for Eczema

     Health via Yahoo News· 7 months ago

     Eczema (also known as dermatitis) is a condition that primarily affects the skin, causing dryness, itchiness, scaliness, rashes, and blisters. In some...

8. • 

     Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag

     Zacks via Yahoo Finance· 2 weeks ago

     Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with...

9. • 

     Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales

     Investor's Business Daily· 6 months ago

     Regeneron Pharmaceuticals and Sanofi said Monday their blockbuster drug, Dupixent, significantly...

10. • 

      ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study

      Zacks via Yahoo Finance· 3 months ago

      ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with...